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Abstract
Background: Scale-up of highly active antiretroviral treatment therapy (HAART) programs in Rwanda has been highly
successful but data on adherence is limited. We examined HAART adherence in a large cohort of HIV+ Rwandan women.
Methods: The Rwanda Women’s Interassociation Study Assessment (RWISA) was a prospective cohort study that assessed
effectiveness and toxicity of ART. We analyzed patient data 1263 months after HAART initiation to determine adherence
rates in HIV+ women who had initiated HAART.
Results: Of the 710 HIV+ women at baseline, 490 (87.2%) initiated HAART. Of these, 6 (1.2%) died within 12 months, 15
others (3.0%) discontinued the study and 80 others (19.0%) remained in RWISA but did not have a post-HAART initiation
visit that fell within the 1263 month time points leaving 389 subjects for analysis. Of these 389, 15 women stopped their
medications without being advised to do so by their doctors. Of the remaining 374 persons who reported current HAART
use 354 completed the adherence assessment. All women, 354/354, reported 100% adherence to HAART at the post-HAART
visit. The high self-reported level of adherence is supported by changes in laboratory measures that are influenced by
HAART. The median (interquartile range) CD4 cell count measured within 6 months prior to HAART initiation was 185 (128,
253) compared to 264 (182, 380) cells/mm
3 at the post-HAART visit. Similarly, the median (interquartile range) MCV within 6
months prior to HAART initiation was 88 (83, 93) fL compared to 104 (98, 110) fL at the 1263 month visit.
Conclusion: Self-reported adherence to antiretroviral treatment 1263 months after initiating therapy was 100% in this
cohort of HIV-infected Rwandan women. Future studies should explore country-specific factors that may be contributing to
high levels of adherence to HAART in this population.
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Introduction
The Human Immunodeficiency Virus (HIV) epidemic has had
a devastating impact on sub-Saharan Africa which contains four
countries with the world’s highest HIV prevalence.[1] As scale-up
highly active antiretroviral treatment (HAART) treatment pro-
grams increase and HAART becomes more available in sub-
Saharan countries, the quality of life for people living with HIV
infection is progressively improving. However, optimal adherence
to HAART is essential for better well-being and increased life
expectancy of HIV-infected individuals accessing treatment and
reduced transmission of HIV. The need for high adherence to
treatment is clearly important in countries such as Zimbabwe,
Botswana and Swaziland where HIV infected individuals make up
as much as 23-26% of the population.[1] But even in other sub-
Saharan countries such as the Comoro islands, Madagascar,
Mauritius and Rwanda where HIV prevalence rates are lower and
scale-up of antiretroviral treatment programs has been successful,
adherence is an essential factor for optimal HIV health outcomes.
Poor adherence to HAART can lead to HIV disease
progression, evolution of drug resistance, and subsequent immu-
nological and clinical failure.[2,3] Adherence to antiretroviral
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and is believed to be a critical determinant of long-term survival
among HIV-infected individuals.[4,5] Non-adherence to these
medications can greatly lower their effectiveness resulting in poor
therapeutic outcomes.[2,3] More than 95% of the prescribed
antiretroviral treatment doses should be taken for optimal
response; lesser adherence is often associated with virologic
failure.[6] Recent studies demonstrate that HIV-infected individ-
uals who adhere to HAART have HIV viral load reduced to levels
so low that HIV transmission is dramatically reduced or
eliminated.[7] Thus, the benefits of adherence to HAART make
it critical to identify factors associated with non adherence that
could lead to increased HIV incidence, treatment failure and drug
resistance.
One meta-analysis of adherence to HAART in sub-Saharan
Africa and North America estimated that only 55% of persons in
the populations studied achieved adequate levels of adherence.[8]
Unfortunately, the studies of adherence in sub-Saharan African
populations used in this meta-analysis were primarily conducted in
patients with early access to limited therapy and further suffered
from small sample sizes. One study in five East African countries
found that less than 50% of facilities routinely measured patient
adherence to HAART and only 25% of these facilities calculated
adherence rates for the clinic population as a whole.[9] In a high
risk urban population in sub-Saharan Africa 38% of patients were
non-adherent to HAART at some point during their treat-
ment.[10] Furthermore, adherence to HAART appears to
decrease steadily over time but may vary by gender and HAART
regimen.[11] In Rwanda, where HIV prevalence is 2.9% and
approximately 70,047 HIV+ persons receive HAART, there has
been limited study of both HAART adherence rates and factors
associated non-adherence. [12] This study seeks to improve
knowledge of HAART adherence in sub-Saharan Africa by
examining adherence to HAART in a large cohort of women
enrolled in the Rwanda Women’s Interassociation Study and
Assessment (RWISA).
Methods
Design
We analyzed data collected from participants in RWISA, an
observational prospective cohort study that assessed effectiveness
and toxicity of HAART. RWISA enrolled participants in 2005
with follow-up visits every six months through 2008. Methods in
the RWISA study have been previously described in detail
elsewhere.[13] At baseline, there were 710 HIV-positive women.
Subjects. Women were recruited from the Women’s Equity
in Access to Care and Treatment (WE-ACTx) clinical site in
Kigali, community- based organizations, and other HIV clinical
care sites in Kigali. To be eligible participants had to be 25 years
of age or older, willing to undergo voluntary counseling and testing
for HIV, able to complete an interview in the local Kinyarwanda
language and lived in Rwanda in 1994. All HIV+ women
were antiretroviral naı ¨ve at enrollment. Exposure to single-dose
nevirapine to prevent mother to child transmission of HIV was not
an exclusion criterion. Women were scheduled to initiate HAART
once clinical or laboratory indications identified that they were
eligible by Rwandan national standards. The study protocol and
its consent process were approved by the Rwanda Na-
tional Ethics Committee and the Institutional Review Board of
Montefiore Medical Center, Bronx, NY USA. This analysis was
restricted to women who initiated HAART by their fifth RWISA
visit (within ,2 years) after enrolling in RWISA and returned for a
follow up visit 1263 months after HAART was initiated.
HAART distribution. All HAART medications were
distributed by the central pharmacy housed at the site of the
participant’s care. First line HAART medications included
stavudine (d4T), lamivudine (3TC), and nevirapine (NVP),
zidovudine (AZT), and efavirenz (EFV). The most common
second line medications were abacavir (ABC) and lopinavir/
ritonavir.[13] The pharmacy distributed a one-month supply of
medications to patients receiving HAART. Patients returned to
the clinic monthly to refill their medications. Patients who failed to
return to the clinic had a follow-up home visit scheduled, as
required by the Rwandan national guidelines.
Clinical Laboratory Measurements. CD4 counts were
measured at the National Reference Laboratory of Rwanda by
FACS Count (Becton Dickinson, San Jose ´, CA). Other laboratory
measures were performed at King Faisal Hospital using standard
methods.
Data collection procedures. At baseline and each
subsequent visit, participants underwent a physical examination.
Medical and social history was also collected, including
demographic characteristics and questions regarding the exact
date of HAART initiation (verified by clinic data) and adherence
to HAART as described below. Specimens were taken for
measuring CD4 cell count, full blood count and other laboratory
studies. A trained interviewer re-assured each participant about
strict confidentiality regarding response to HAART adherence
questions and that their responses would not negatively impact
their clinical care. For the analyses presented here, information on
adherence was obtained from all RWISA interviews conducted
1263 months after the participant had initiated HAART. If
multiple visits from the same person fell into this window, the visit
closest to 12 months was chosen.
HAART adherence questionnaire. Participants who had
initiated HAART were asked the following questions regarding
their adherence to HAART medications; ‘‘Have you taken any
medications to fight HIV since your last visit?’’ and ‘‘Are you
currently taking any medications to fight HIV?’’ Participants
whose answer was ‘‘yes’’ were asked, for each medication, ‘‘How
many times per day did you take this medication yesterday, 2 days
ago and 3 days ago?’’, and ‘‘Usually, how many times a day do you
take this medication?’’ The possible answers to all of these
questions were once, twice or three times a day or do not know.
Participants who stopped HAART were also asked whether they
stopped because of side effects, a belief that they no longer needed
medicine or other reasons.
For this study, self reported adherence to antiretroviral therapy
was dichotomized as 100% or ,100% on the basis of a previously
published algorithm.[14] One hundred percent adherence was
defined as taking all doses as prescribed. In contrast, inclusion in
the ,100% adherence group resulted when the participant
reported taking their current medications fewer times than
prescribed.
Statistical Methods
Baseline characteristics were analyzed using descriptive statis-
tics. Medians and interquartile ranges were calculated for
normally distributed continuous variables and proportions for
categorical variables. All statistical data were analyzed using SAS
Version 9.1.3 (Cary, NC).
Results
Of the 710 HIV+ women at baseline, 490 (87.2%) initiated
HAART by the fifth RWISA visit. Of these 15 (3.1%) dropped out
of the RWISA study; 6 (1.2%) died within 12 months after
HAART Adherence in Rwandan Women
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have a post-HAART initiation visit that fell within the 1263
month time points, leaving a total of 389 women for analysis. Of
these 389, 15 women were no longer taking HAART, all of whom
stopped their medications without being advised to do so by their
doctors. Of the remaining 374 persons who reported current
HAARTuse,354responded totheadherencequestions(Figure1).
Baseline characteristics of the cohort are shown in Table 1. The
median age of women in the cohort was 35.5 years. Most women
were poor and unemployed with little to no formal education.
Many women had World Health Organization (WHO) stage 4
HIV illness defined either with or without the weight loss
criterion, 56% and 42% respectively, at some point during their
treatment.
The last visit within 6 months prior to HAART initiation tended
to be a little over 2 months (median =65.5 days) prior to the date
of initiating antiretroviral treatment. The date of the visit closest to
12 months post HAART initiation (the post-HAART visit) tended
to be almost one year (median =347.5 days) following the start
date of antiretroviral treatment. All women, 354/354, reported
100% adherence to HAART at the post-HAART visit. As
adherence was 100%, further analyses of predictors of non-
adherence were not undertaken.
For the 354 women who reported 100% adherence to
HAART the median (interquartile range) CD4 cell count
measured within 6 months prior to HAART initiation was 185
(128, 253) compared to 264.5 (182, 380) cells/mm
3 at the post-
HAART visit. Similarly, the median (interquartile range) MCV
within 6 months prior to HAART initiation was 88 (83, 93) fL
compared to 104 (98, 110) fL at the 12-month post-HAART
initiation visit.
Discussion
Our study indicates that self-reported adherence to antiretro-
viral treatment 1263 months after initiating therapy was 100%
(354/354) in this cohort of HIV-infected Rwandan women. Even
considering the 15 women who had started HAART and quit
taking their medications without being advised to do so by their
doctors and the other 20 who did not answer the adherence
questions as nonadherers, a worst-case adherence would be 91.0%
(354/389). Furthermore, the attrition rate was low with only 3%
(15/490) of women not returning for any follow-up visits beyond
12 months post HAART initiation. This rate of attrition is much
lower than seen in other sub-Saharan African countries.[15]
Adherence in this study is higher than reported elsewhere
including from other African and non-African countries.[8,16,17]
For instance, in a study assessing factors associated with
medication adherence in HIV-infected adults in Botswana, overall
adherence was 81%.[16] In Nigeria, a similar study showed
adherence rates to HAART of approximately 75%.[17] Our
findings, however, are consistent with an earlier small study of
adherence to HAART in Rwanda. A 2003 study in the Ensemble
de Solidarite Therapeutique Hospitaliere En Reseau (ESTHER)
antiretroviral treatment program at the Centre Hospitalier
Universitaire de Kigali in Kigali, Rwanda, found that only 5%
of patients reported missing a dose of their HAART medication in
the 3 days prior to their adherence visit.[18] This level of
adherence was confirmed using therapeutic drug monitoring in a
group of 41 patients taking Triomune or Triviro (single-pill fixed
dose combinations of stavudine/lamivudine/nevirapine). Only 5%
of patients in this group had undetectable drug levels and 93% had
levels within the therapeutic range.[18]
Figure 1. Flow diagram of RWISA Adherence Cohort. RWISA, Rwanda Women’s Interassociation Study Assessment; HIV, Human
immunodeficiency virus; HAART, Highly active antiretroviral therapy.
doi:10.1371/journal.pone.0027832.g001
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prompted us to informally compare our findings with other
Rwandan health facilities. Three of the authors [SM, EM, FM]
looked at HAART adherence rates by examining clinical
pharmacy statistics at King Faisal Hospital Kigali (KFH, K),
WE-ACTx and Gicumbi Hospital respectively. Pharmacy data
from KFH, K indicated that 94% (367/400) of patients on
HAART returned to refill their medications within three days of
their scheduled appointment during September to December
2010, and between January to February 2011, 100% (400/400) of
patients returned to fill their medications. Similarly, in the first
quarter of 2010, 94% (1071/1139) of patients on HAART at the
WE-ACTx clinic refilled their medications at the appropriate time.
For the last quarter of 2010, 93% (2081/2237) of patients on
HAART at Gicumbi Hospital appropriately refilled their medi-
cations.
Another indication that the level of adherence found in this
study is accurate can be assessed by analyzing the observed
changes in CD4 cell count and MCV from zero to six months
prior to HAART initiation to approximately 12 months post
HAART initiation. On a population level median CD4 cell counts
rose about 80 cells/mm
3 from 185 to 265 while median MCV
increased about 16 fL from 88 to 104. The observed 80 cells/mm
3
change in CD4 cell count is consistent with data from clinical trials
which demonstrate that patients on HAART with good virologic
control show an average increase of approximately 50–100 cells/
mm
3 per year until a steady state level is achieved.[19] The
observed rise in median MCV of 16 fL from 88 to 104 may also
indicate adherence to HAART for those patients taking
zidovudine or stavudine. Prior studies have correlated the
development of macrocytosis with zidovudine and stavudine use
and suggested that simple observations of patients’ MCV could be
an effective method of monitoring antiretroviral adherence.[20]
While we considered looking at individual changes in MCV and
CD4 to see if these could identify specific non-adherers who were
misreporting adherence, the repeat visit random change and
measurement error of laboratory parameters such as this is so high
as to negate this use of between visit changes.[21]
There are several possible reasons why adherence in this cohort
of Rwandan women could be very high. Unlike many other
settings, in Rwanda, when a patient becomes eligible to start
antiretroviral treatment, national guidelines require that person to
attend 2- to 3-day educational sessions with a ‘‘buddy’’ who can
support his or her adherence to HAART.[22] There are
mandatory social criteria for starting HAART, including accep-
tance to be visited by a health care worker, having a trusted person
Table 1. Participants characteristics at 1263 months post HAART visit.
CONTINUOUS CHARACTERISTICS (n=354 except if noted otherwise) Median (Interquartile Range)
Age (years) 35.5 (32.5, 41.0)
Body Mass Index (BMI) (Kg/m
2) (n=349) 22.3 (20.2, 24.2)
Days from last Pre-HAART visit to date of HAART initiation 65.5 (20, 107)
Days HAART initiation to closest visit to 12 months post HAART initiation 347.5 (309, 390)
CD4 count 0-6 months pre-HAART 185 (128, 253)
CD4 count 12 months Post-HAART 264.5 (182, 380)
MCV 0-6 months pre-HAART (n=314) 88 (83, 93)
MCV 12 months post-HAART (n=327) 104 (98, 110)
CATEGORICAL CHARACTERISTICS (n=354 except if noted otherwise) n (%)
Raped in Genocide (n=350) 183 (52.3%)
Employed 31 (8.8%)
Had fever .2 weeks 24 (6.8%)
Usual number of HAART medications/day
1 per day 2 (0.6%)
2 per day 352 (99.4%)
Education (n=349)
No schooling 77 (22.1%)
Some primary school 128 (36.7%)
Secondary or University 144 (41.3%)
Income per month (Frw) (1 USD=602 Frw) (n=351)
,10 K 152 (43.3%)
10–35 K 166 (47.3%)
.35 K 33 (9.4%)
Had WHO stage 4 illness with weight loss at pre ARV 296 (55.4%)
Had WHO stage 4 illness without weight loss pre ARV 149 (42.1%)
Adherent to HAART medication
a 354 (100%)
aBased on taking the required number of doses in the previous s days according to a previously published algorithm [12].
doi:10.1371/journal.pone.0027832.t001
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a fixed residence within Rwanda in a known catchment area of a
health facility and disclosure of HIV status to a trusted family
member. To further promote adherence, there are also follow up
visits at the village level guided by a community health worker and
or a member of associations of people living with HIV and AIDS.
Certain cultural aspects of Rwandan society may also contribute
to high levels of HAART adherence. Following the 1994 war and
genocide there has been a strong societal focus on community
coherence and the sharing of meager resources. Within this
communal environment the loss of a family member is a loss to the
whole village or umudugudu and to a wider Rwandan community;
thus, there is a strong focus on promoting health and reducing
morbidity and mortality. Family members within a community are
obliged by custom to support an HIV-infected person through the
journey of compliance to antiretroviral therapy.
Other national characteristics specific to Rwanda may have
contributed to the high adherence to HAART seen in this study.
In Rwanda there is almost universal health coverage with 96% of
Rwandans having health insurance, 91% of which is provided
through the government-supported Mutuelle de Sante ´ pro-
gram.[22] Furthermore, in Rwanda there is a strong emphasis
on personal and public health. For example, immunization
coverage for children under one year of age for the six killer
diseases (tuberculosis, poliomyelitis, tetanus, diphtheria, pertussis,
measles) is the highest globally with 100% coverage as reported by
both national statistics and UNICEF.[23] Lastly, in Rwanda, all
HAART medications are provided free of charge to patients once
they meet eligibility criteria for treatment initiation. The general
promotion of health, almost universal insurance coverage and
availability of medical care and free medications all likely
contribute to better overall HAART adherence.
Some limitations of this analysis should be noted. Our study was
in a cohort consisting entirely of Rwandan women and may not be
generalizable to other sub-Saharan African populations. Prior
studies have indicated that women may have higher HAART
adherence compared to men.[17,24,25] This gender disparity
could have been a contributing factor to the high adherence found
in this study. All study participants were being followed as part of a
larger research study. The majority of these participants received
their HIV care at a non-governmental organization clinic where
there were greater outreach efforts such as patient home visits
and extra resources invested in care and treatment of women.
Although there are remarkable initiatives to improve adherence
even in government health care clinics, the extra resources and
close follow-up for majority of patients in RWISA cohort study,
could have resulted in better overall adherence compared to the
general population. While only 15 of the 490 women who began
HAART dropped out of the study we did not have adherence data
for the 6 woman who died prior to 1263 months post HAART
initiation. There were an additional 80 women who remained in
RWISA but did not have a study visit within the 1263 months
time points designated for this study. The median time from
HAART initiation to follow-up for these 80 women was 639 days.
Similar to the 1263 month cohort 4 women had stopped HAART
without being told to do so by their physician and the remaining
76 women reported 100% adherence. This adherence measure-
ment occurred outside of the 1263 months time frame set for this
study so this data was not included in our analysis.
We measured HAART adherence by self-report using struc-
tured interview questions that can be subject to overestimation as
patients tend to overstate their adherence to treatment. Other
measures of adherence, such as pill counts, pharmacy records,
electronic devices or therapeutic drug monitoring were not
available to us. Even so, measuring adherence using patients’
self-report can be easily replicated in most resource-limited settings
including Rwanda making it a good measure for comparison. We
examined the median CD4 cell count and MCV at the pre and
post adherence visit to corroborate the self-reported adherence of
the study participants. Given the significant variability in these
between-visit hematologic parameters it is possible that individual-
based changes could be due in part to underlying variability in the
observed data.[21,26,27] However, due to the central limit
theorem when comparing median CD4 cell counts (or MCV
levels) in a sample size this large (354) such variability tends to
cancel out, making population-based comparisons a more reliable
indicator of what is happening in the population as a whole.[21]
Lastly, we chose to define adherence as taking all prescribed
HAART medications as directed in the three days prior to the
1263 months adherence visit. This definition of adherence has
been used in prior studies which observed substantially lower rates
of adherence than we observed.[28,29] We did not ask patients if
they had missed medication doses in the month prior to their clinic
visit or if they ‘‘more generally take most or nearly all of their
prescribed medications’’. It can be argued that this single pre-clinic
visit measurement of adherence may not accurately reflect more
general adherence.
In conclusion, adherence to highly active antiretroviral
treatment at one year after initiation of HAART in this cohort
of Rwandan women appears to be extremely high. Numerous
social, cultural and political factors specific to Rwanda, and the
structured required outreach to patients not coming into the
pharmacy for refills, likely contribute to this high level of
adherence. Future studies in Rwanda will be needed to determine
the level of long-term adherence to HAART and if adherence
rates change over time. More research is needed to determine
which country specific factors may be contributing to the high
levels of adherence to HAART in this population.
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